Tiziana Life Sciences Ltd (TLSA) Form 6-K — Jul 22, 2026
Tiziana Life Sciences announced that Executive Chairman Gabriele Cerrone increased his beneficial ownership through an entity he controls. The purchase of 42,357 common shares at $0.99 per share brings his total holding to 44,814,587 shares, representing 34.93% of the company's issued share capital. The company's lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in a Phase 2a trial for non-active secondary progressive multiple sclerosis. An Expanded Access Program has shown disease improvement or stability in all 14 patients treated within six months.
Key figures
- Shares purchased
- 42357
- Percent ownership
- 34.93
- Purchase price per share
- 0.99
- Total shares held by insider
- 44814587
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.